Research Misconduct NHS: How Governance Differs from University Policy

Research misconduct NHS allegations are not resolved as a purely internal university disciplinary matter. Because a designated research sponsor and the Health Research Authority (HRA) hold formal accountability under the UK Policy Framework for Health and Social Care Research, misconduct in NHS-hosted clinical studies routes through trust-level research governance and, for doctors, potential General Medical Council scrutiny — running alongside, not instead of, any university process.

Research misconduct is behaviour that deliberately or recklessly falls short of the standards expected in the conduct of research, spanning fabrication, falsification, plagiarism, and breaches of the ethical or regulatory approvals a study depends on.

• What Counts as Research Misconduct in NHS-Hosted Research?
• Who Investigates? The Sponsor, the HRA and Trust Governance
• NHS Research Misconduct vs University Procedures: Where They Diverge
• What Dual-Employment Researchers Need to Know
• Frequently Asked Questions

What Counts as Research Misconduct in NHS-Hosted Research?

In an NHS setting, research misconduct covers the same core categories recognised across UK research generally, but with an added patient-safety dimension. Proceeding without the ethics approval, HRA Approval, or informed consent a study requires is treated as seriously as fabricating data.

• Fabrication or falsification of results, including patient consent records
• Plagiarism of ideas, protocols, or published text
• Undeclared conflicts of interest affecting clinical decision-making
• Conducting research without the required ethical or regulatory permissions in place
• Deviating from an approved protocol without reporting the change

The UK Research Integrity Office (UKRIO) frames this as behaviour that “deliberately or recklessly” falls short of expected standards — a threshold that separates genuine misconduct from honest error, which most NHS trust policies classify instead as a “questionable research practice” requiring correction rather than disciplinary action.

Who Investigates? The Sponsor, the HRA and Trust Governance

The pivotal difference from a university-only inquiry is the statutory concept of the research sponsor. Under the UK Policy Framework for Health and Social Care Research (Health Research Authority and the four UK health departments, first published 2017), the sponsor — usually the NHS trust, a university, or a commercial entity — takes on legal responsibility for confirming a study’s initial and ongoing suitability.

This changes who is notified and when:

• The NHS trust’s Research and Development (R&D) office, or the trust’s Director of Research, typically leads the initial assessment of an allegation raised on trust premises
• Serious breaches of Good Clinical Practice or the approved protocol in a clinical trial must be reported by the sponsor to the HRA (and, for medicines trials, the MHRA) within statutory timeframes — a duty that has no direct equivalent in a purely observational university study
• The relevant NHS Research Ethics Committee must be informed where the breach affects participant safety or the ethical basis of the study
• Where fraud is suspected, the NHS Counter Fraud Authority can be engaged in parallel to any research-integrity investigation
• For registered doctors, nurses, or other regulated professionals, a finding of misconduct can trigger a separate referral to the General Medical Council or equivalent professional regulator, independent of the employer’s own outcome

UKRIO’s model procedure — the template most university codes of practice are built on — is advisory rather than statutory. NHS research governance, by contrast, sits inside a framework with mandatory reporting duties attached to the sponsor role, which is why an allegation in an NHS-hosted trial can trigger regulatory notifications a university-only investigation would never generate.

NHS Research Misconduct vs University Procedures: Where They Diverge

Both systems share the same underlying commitments — the Concordat to Support Research Integrity (Universities UK, 2019) and UKRIO’s guidance inform both — but the accountable parties and mandatory notifications differ sharply.

The practical effect: an NHS-hosted allegation can generate two or more concurrent processes — sponsor/trust governance and, if a professional regulator becomes involved, a fitness-to-practise track — whereas a university-only case usually resolves within a single institutional procedure.

What Dual-Employment Researchers Need to Know

Most clinical academics hold a substantive university post alongside an honorary research contract or “letter of access” with an NHS trust, arranged through the NHS Research Passport system. This dual status means an allegation can, in principle, be picked up by either employer’s procedure — or both.

• Establish early which organisation is the study’s sponsor: sponsor obligations under the UK Policy Framework sit with that entity, not automatically with the employer
• Expect the university and the NHS trust to agree a lead institution for the investigation, informed by UKRIO’s guidance on cross-institutional cooperation, with the second body kept informed rather than running a parallel duplicate inquiry
• Understand that an honorary contract does not exempt a researcher from either institution’s disciplinary powers — sanctions (suspension of research privileges, restriction of clinical duties, dismissal) can be applied independently by each party
• Keep records of ethical approvals, protocol versions, and consent documentation accessible to both employers, since a trust R&D office and a university research office may request the same evidence separately

Research administrators supporting joint appointments should confirm, before a study opens, which institution’s misconduct procedure will apply if a concern is raised — this sits alongside the wider governance responsibilities covered under research administration frameworks.

Frequently Asked Questions

What is an example of misconduct in the NHS?

In an NHS research context, a documented example is proceeding with a clinical trial without valid ethics approval or falsifying patient consent records. Both breach the UK Policy Framework for Health and Social Care Research and trigger sponsor reporting duties to the Health Research Authority, independent of any wider workplace conduct issue.

What are the three types of research misconduct?

The three most widely recognised categories are fabrication (inventing data or results), falsification (manipulating data, materials, or processes to misrepresent findings), and plagiarism (using others’ work or ideas without acknowledgement). UK bodies including UKRIO also recognise a broader “questionable research practices” category for less severe lapses.

What is considered the most serious form of research misconduct?

Fabrication of results or consent data is generally treated as the most serious category, because it directly corrupts the evidence base and, in clinical research, can endanger patient safety. In NHS-hosted studies, fabrication findings typically prompt both sponsor notification to the HRA and professional regulator referral for the individual involved.

What is a sackable offence in NHS?

A confirmed finding of fabrication or falsification in NHS-hosted research is normally treated as gross misconduct and can constitute a sackable offence under trust disciplinary policy. For registered clinicians, the same finding can additionally trigger a General Medical Council fitness-to-practise referral, separate from the employer’s own decision.

The structural distinction matters beyond individual cases. As more clinical trials run through joint university–NHS sponsorship arrangements, institutions that treat research governance as a single, unified track — rather than mapping sponsor, trust, and employer obligations separately — risk missing mandatory notifications the UK Policy Framework requires. Clear, pre-agreed lead-institution protocols for dual-employment researchers remain the most effective safeguard.